Skip to main content

Table 2 Characteristics related to prior and retreatment anti-EGFR regimens

From: Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response

Characteristic N/total # pts (%)
Response on prior anti-EGFR therapy
  Response or stable disease ≥6 m 37/89 (42)
  No response or stable disease <6 m 52/89 (58)
Clinical benefit on anti-EGFR retreatment  
  Best response CR/PR/SD 50/86 (58)
  Best response PD 36/86 (42)
Prior anti-EGFR-based regimens  
  Panitumumab monotherapy 6/89 (7)
  Panitumumab + Chemotherapya 9/89 (10)
  Panitumumab and AMG-102/AMG-479 1/89 (1)
  Cetuximab monotherapy 2/89 (2)
  Cetuximab + Chemotherapyb 71/89 (80)
Anti-EGFR-based retreatment regimens  
  Cetuximab, FOLFOX, and dasatinib 31/89 (35)
  Cetuximab, irinotecan, and bevacizumab 12/89 (13)
  Cetuximab and erlotinib 13/89 (15)
  Cetuximab and sirolimus 11/89 (12)
  Cetuximab, HAIc oxaliplatin, 5-FU, bevacizumab 20/89 (23)
  Cetuximab, HAI oxaliplatin, and bevacizumab 2/89 (2)
Interval length between prior and retreatment anti-EGFR therapies Months
  Median 4.57
  Mean ± Standard Deviation 7.34 ± 8.9
  Range 0.46 – 58.7
  1. aChemotherapy regimen: irinotecan (7), FOLFIRI (1), 5-FU and irinotecan (1)
  2. bChemotherapy regimen: Irinotecan (42), FOLFIRI (15), FOLFOX (5), irinotecan and arq197 (3), irinotecan and apomab (1), irinotecan and bevacizumab (3), FOLFOX and dasatinib (1), Xelox (1)
  3. cHAI = Hepatic Arterial Infusion
Back to article page